ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)

被引：43

作者：

Solomon, B. J. ^{[1
]}

Ahn, J. S. ^{[2
]}

Dziadziuszko, R. ^{[3
,4
]}

Barlesi, F. ^{[5
]}

Nishio, M. ^{[6
]}

Lee, D. H. ^{[7
]}

Lee, J. S. ^{[8
]}

Zhong, W. Z. ^{[9
]}

Horinouchi, H. ^{[10
]}

Mao, W. ^{[11
]}

Hochmair, M. J. ^{[12
]}

De Marinis, F. ^{[13
]}

Migliorino, M. R. ^{[14
]}

Bondarenko, I. ^{[15
]}

Lohmann, T. O. ^{[16
]}

Xu, T. ^{[17
]}

Gavaldon, A. Cardona ^{[18
]}

Bordogna, W. ^{[19
]}

Ruf, T. ^{[20
]}

Wu, Y. L. ^{[21
]}

机构：

[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[2] Samsung Med Ctr, Dept Hematol Oncol, Seoul, South Korea

[3] Med Univ Gdansk, Dept Oncol Radiotherapy, Gdansk, Poland

[4] Med Univ Gdansk, Early Phase Clin Trials, Gdansk, Poland

[5] Int Ctr Thorac Cancers CICT, Dept Med Oncol, Villejuif, France

[6] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

[7] Asan Med Ctr, Dept Oncol, Seoul, South Korea

[8] Seoul Natl Univ, Div Hematol & Med Oncol, Dept Internal Med, Bundang Hosp, Seongnam, South Korea

[9] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China

[10] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[11] Chinese Acad Sci, Inst Basic Med & Canc, Hangzhou, Zhejiang, Peoples R China

[12] Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp Crit Care Med, Klin Floridsdorf, Vienna, Austria

[13] European Inst Oncol IRCSS, Thorac Oncol Div, Milan, Italy

[14] San Camillo Forlanini Hosp, Pneumo Oncol Unit, Rome, Italy

[15] Dnipropetrovsk Med Acad, Oncol & Med Radiol Dept, Dnipro, Ukraine

[16] F Hoffmann Roche Ltd, PD Oncol, Basel, Switzerland

[17] Roche China Holding Ltd, Dept Clin Sci, Shanghai, Peoples R China

[18] F Hoffmann Roche Ltd, Data & Stat Sci, Basel, Switzerland

[19] F Hoffmann Roche Ltd, Product Dev Med Affairs, Basel, Switzerland

[20] F Hoffmann Roche Ltd, PD Safety Risk Management, Basel, Switzerland

[21] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.051

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA2

引用

页码：S1295 / S1296

页数：2

共 50 条

[1] ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)
Shah, Rajiv
Solomon, Benjamin J.
Ahn, Jin Seok
Dziadziuszko, Rafal
Barlesi, Fabrice
Nishio, Makoto
Lee, Dae Ho
Lee, Jong-Seok
Zhong, Wenzhao
Horinouchi, Hidehito
Mao, Weimin
Hochmair, Maximilian
de Marinis, Filippo
Migliorino, Maria Rita
Bondarenko, Igor
Lohmann, Tania Ochi
Xu, Tingting
Cardona, Andres
Bordogna, Walter
Ruf, Thorsten
Wu, Yi-Long
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 243 - 244
[2] Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK plus non-small cell lung cancer (NSCLC): A sub analysis of ALINA
Ahn, J. S.
Wu, Y-L.
Dziadziuszko, R.
Barlesi, F.
Nishio, M.
Lee, D. H.
Lee, J-S.
Zhong, W-Z.
Horinouchi, H.
Mao, W.
Lu, S.
Wang, Q.
Yang, C-T.
Korphaisarn, K.
Xu, T.
Bu, L.
Scalori, A.
Petric, P.
Redhead, K.
Solomon, B.
ANNALS OF ONCOLOGY, 2023, 34 : S1646 - S1647
[3] ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK plus NonSmall Cell Lung Cancer (NSCLC)
Horinouchi, H.
Solomon, B. J.
Wu, Y. L.
Barlesi, F.
Nishio, M.
Ahn, J. S.
Lee, D. H.
Lee, J. S.
Zhong, W.
Hochmair, M.
Bondarenko, I.
Planchard, D.
Rittmeyer, A.
Ding, B.
Ruf, T.
Adler, L.
Scalori, A.
Dziadziuszko, R.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S39 - S39
[4] ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK plus non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)
Solomon, B. J.
Wu, Y-L.
Dziadziuszko, R.
Barlesi, F.
Nishio, M.
Ahn, J. S.
Horinouchi, H.
Hochmair, M. J.
de Marinis, F.
Migliorino, M. R.
Kurochkin, A.
Harputluoglu, H.
Planchard, D.
Korphaisarn, K.
Han, J-Y.
Lohmann, T.
Gavaldon, A. Cardona
Archer, V. R.
Nowicka, M.
Noe, J.
ANNALS OF ONCOLOGY, 2024, 35 : S775 - S775
[5] ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB IIIA anaplastic lymphoma kinase-positive (ALK plus ) non-small cell lung cancer (NSCLC).
Solomon, Benjamin J.
Ahn, Jin Seok
Barlesi, Fabrice
Dziadziuszko, Rafal
Nishio, Makoto
Shaw, Alice Tsang
Bordogna, Walter
Meyenberg, Christoph
Wu, Yi-Long
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer
Inamura, Kentaro
JAMA ONCOLOGY, 2021, 7 (04) : 637 - 638
[7] Adjuvant chemotherapy for early-stage non-small cell lung cancer
Visbal, AL
Leighl, NB
Feld, R
Shepherd, FA
CHEST, 2005, 128 (04) : 2933 - 2943
[8] Adjuvant chemotherapy in early-stage non-small cell lung cancer
Dômont, J
Soria, JC
Le Chevalier, T
SEMINARS IN ONCOLOGY, 2005, 32 (03) : 279 - 283
[9] COST OF IMPLEMENTING ALECTINIB AS AN ADJUVANT TREATMENT FOR ALK plus NON-SMALL CELL LUNG CANCER IN DENMARK (C-ALINA)
Beck, C.
Fanoe, A.
Hillring, P.
Urbanskac, E. M.
Meldgaard, P.
VALUE IN HEALTH, 2024, 27 (12) : S130 - S130
[10] Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK plus non-small cell lung cancer (NSCLC): Data from ALINA
Nishio, Makoto
Wu, Yi-Long
Barlesi, Fabrice
Ahn, Jin Seok
Lee, Dae Ho
Lee, Jong-Seok
Zhong, Wenzhao
Horinouchi, Hidehito
Hochmair, Maximilian
Tanaka, Hiroshi
Glogowski, Maciej
Rittmeyer, Achim
Fidler, Mary J.
Wrona, Anna
Mamolo, Carla
Cardona, Andres
Ruf, Thorsten
Smoljanovic, Vlatka
Solomon, Benjamin J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →